Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application

Laser blended vision (Presbyond) for presbyopia correction

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Refractive
Session Date/Time: Friday 09/02/2018 | 10:30-12:00
Paper Time: 11:12
Venue: Annex A

First Author: M.Soyler TURKEY
Co Author(s): H. Sabur  S. Bilis  V. Dayanir           

Abstract Details


To evaluate the outcomes of LASIK-induced non-linear aspheric micro-monovision for the correction of presbyopia with myopia, astigmatism, hyperopia or emmetropia


Retrospective Study/ Batıgöz Hospital


This retrospective study included 64 patients who underwent LASIK-induced micro-monovision for the correction of presbyopia with MEL 90 excimer laser (Carl Zeiss Meditec). Flaps were created using either VisuMax (Carl Zeiss Meditec) or IFS (Abbott Medical Optics) femtosecond laser. A non-linear aspheric ablation profile was used to increase the spherical aberration in both eyes The target refraction was plano for distant eyes (dominant eye) and a slight myopia of -1,5 D for near eyes. Preoperative and postoperative uncorrected distant visual acuity (UDVA), uncorrected near visual acuity (UNVA), patient satisfaction, safety, need for retreatment, complications and follow-up time were recorded.


Among 64 patients, 18 (28.2%) patients were emmetropic, 14 (21.8%) were myopic or myopic astigmatic, and 32 (50%) were hyperopic or hyperopic astigmatic. Median age was 51 years (range: 40 to 71 years). Mean follow-up was 6.1 months (range: 1 month to 9 months). Binocularly, 98% of patients achieved UDVA 20/20; 95% achieved uncorrected near visual acuity of J2. Regarding safety, one eye lost 2 or more lines of best spectacle-corrected visual acuity. 95% of the patients were satisfied with their results at 6 months after surgery.


Laser Blended Vision®(Presbyond) is a safer and effective procedure for treating patients with both myopia, hyperopia or emmetropia. Patient selection seems important for getting satisfactory results.

Financial Disclosure:


Back to previous